Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Viatris's Q3 2024 results showcased key elements both bolstering and challenging its financial position.</li><li>Notably, the company delivered significant revenue growth, with total revenues reaching $3.8 billion, a 3% increase on an operational basis.</li><li>Additionally, Viatris achieved its sixth consecutive quarter of growth in terms of adjusted EBITDA and adjusted earnings per share (EPS).</li></ul>

Viatris's Q3 2024 results showcased key elements both bolstering and challenging its financial position.Notably, the company delivered significant revenue growth, with total revenues reaching $3.8 billion, a 3% increase on an operational basis.Additionally, Viatris achieved its sixth consecutive quarter of growth in terms of adjusted EBITDA and adjusted earnings per share (EPS).

Viatris Inc.: Expansion of Innovative Portfolio As A Vital Factor Driving Growth! - Major Drivers

<ul><li>Viatris has delivered a solid performance in the second quarter of 2024, marking the fifth consecutive quarter of operational revenue growth.</li><li>Under the leadership of CEO Scott Smith, the company, which was formed from the merging of Mylan and Upjohn, a division of Pfizer, has effectively integrated two global entities and streamlined its operations through strategic divestitures.</li><li>This strategic realignment has evidently positioned Viatris at a pivotal point for future growth, focusing strongly on expanding its innovative products alongside its stable base business.</li></ul>

Viatris has delivered a solid performance in the second quarter of 2024, marking the fifth consecutive quarter of operational revenue growth.Under the leadership of CEO Scott Smith, the company, which was formed from the merging of Mylan and Upjohn, a division of Pfizer, has effectively integrated two global entities and streamlined its operations through strategic divestitures.This strategic realignment has evidently positioned Viatris at a pivotal point for future growth, focusing strongly on expanding its innovative products alongside its stable base business.

Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! - Major Drivers

<ul><li>Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals.</li><li>These include maintaining base business stability, driving new product revenue, and focusing on key strategic initiatives that spur future growth.</li><li>Viatris announced its successful acquisition of Idorsia and its strategic R&D plans for the recent acquisitions – selatogrel and cenerimod.</li></ul>

Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals.These include maintaining base business stability, driving new product revenue, and focusing on key strategic initiatives that spur future growth.Viatris announced its successful acquisition of Idorsia and its strategic R&D plans for the recent acquisitions – selatogrel and cenerimod.

<ul><li>Viatris Inc.</li><li>reported its Q4 and Full Year 2023 Earnings with strong operational results, showing revenue growth for the third consecutive quarter.</li><li>As Viatris begins 2024, it continues to generate strong free cash flows that provide the flexibility to balance capital return to shareholders and strategic investments for future growth.</li></ul>

Viatris Inc.reported its Q4 and Full Year 2023 Earnings with strong operational results, showing revenue growth for the third consecutive quarter.As Viatris begins 2024, it continues to generate strong free cash flows that provide the flexibility to balance capital return to shareholders and strategic investments for future growth.

Viatris Inc.: Strategic Expansion Into Key Therapeutic Verticals & 6 Other Major Drivers

<ul><li>Viatris' results were a major disappointment as the company failed to meet Wall Street's revenue and earnings expectations.</li><li>During the third quarter, Viatris delivered total revenues of $3.94 billion, showcasing approximately 1% year-over-year growth, surpassing expectations with an adjusted EBITDA of $1.36 billion and free cash flow of $738 million.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

Viatris' results were a major disappointment as the company failed to meet Wall Street's revenue and earnings expectations.During the third quarter, Viatris delivered total revenues of $3.94 billion, showcasing approximately 1% year-over-year growth, surpassing expectations with an adjusted EBITDA of $1.36 billion and free cash flow of $738 million.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Viatris Inc.: The Blueprint for Conquering the Global Pharma Market! - Major Drivers

United States

Viatris Inc. operates as a pharmaceutical company. The Company produces medicines for patients across broad range of major therapeutic areas spanning both noncommunicable and infectious diseases. Viatris serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Viatris (VTRS US)

Viatris Inc.: Expansion of Innovative Portfolio As A Vital Factor Driving Growth! - Major Drivers

Viatris's Q3 2024 results showcased key elements both bolstering and challenging its financial position. Notably, the company delivered...

Baptista Research

Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! - Major Drivers

Viatris has delivered a solid performance in the second quarter of 2024, marking the fifth consecutive quarter of operational revenue...

Baptista Research

Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! - Major Drivers

Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals. These include maintaining...

Baptista Research

Viatris Inc.: Strategic Expansion Into Key Therapeutic Verticals & 6 Other Major Drivers

Viatris Inc. reported its Q4 and Full Year 2023 Earnings with strong operational results, showing revenue growth for the third consecutive...

Baptista Research

Viatris Inc.: The Blueprint for Conquering the Global Pharma Market! - Major Drivers

Viatris' results were a major disappointment as the company failed to meet Wall Street's revenue and earnings expectations. During the third...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)